FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Metastatic urothelial carcinomaLocally Advanced Urothelial CarcinomaUrothelial Carcinoma of the Urinary Bladder+ [3]

Inactive Indication

Advanced Gastric AdenocarcinomaAdvanced LymphomaBreast Cancer+ [14]

Originator Organization

AstraZeneca PLC

Active Organization

AstraZeneca PLC

Abbisko Therapeutics Co., Ltd.Wuxi Heyu Biomedical Technology Co., Ltd.

Inactive Organization

National Cancer Institute

Drug Highest PhasePhase 2

First Approval Date-

RegulationOrphan Drug (US)

Structure

Molecular FormulaC26H33N5O3

InChIKeyVRQMAABPASPXMW-HDICACEKSA-N

CAS Registry1035270-39-3

Clinical Trials associated with Fexagratinib

CTR20222326 / RecruitingPhase 2

一项开放的评价 AZD4547 联合替雷利珠单抗治疗存在 FGFR 改变的局部晚期或转移性尿路上皮癌患者的有效性和安全性的II期临床研究

[Translation] An open-label phase II clinical study evaluating the efficacy and safety of AZD4547 combined with tislelizumab in patients with locally advanced or metastatic urothelial carcinoma with FGFR alterations

A部分：主要目的：评估AZD4547联合替雷利珠单抗治疗局部晚期或转移性尿路上皮癌患者的安全性与耐受性；确认B部分的临床研究联合疗法的剂量和模式。次要目的：初步评估AZD4547联合替雷利珠单抗治疗局部晚期或转移性尿路上皮癌的抗肿瘤活性；评估AZD4547联合替雷利珠单抗连续给药的PK特征。探索性目的：探索AZD4547的PD特征以及PD与PK的相关性：B部分：主要目的：评估AZD4547联合替雷利珠单抗治疗存在FGFR2/3改变的局部晚期或转移性尿路上皮癌患者的抗肿瘤活性。次要目的：评估AZD4547联合替雷利珠单抗治疗存在FGFR2/3改变的局部晚期或转移性尿路上皮癌患者的其他抗肿瘤活性；评估AZD4547联合替雷利珠单抗治疗存在FGFR2/3改变的局部晚期或转移性尿路上皮癌患者的安全性与耐受性；评估AZD4547的药代动力学特征；探索性目的：探索AZD4547的PD特征以及PD与PK的相关性；抗肿瘤疗效与肿瘤微环境免疫特征和基因组特征之间的关系；探索AZD4547联合替雷利珠单抗治疗存在FGFR2/3改变的局部晚期或转移性尿路上皮癌患者的疗效。

[Translation]

Part A: Primary objective: To evaluate the safety and tolerability of AZD4547 combined with tislelizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma; to confirm the dose and mode of clinical study combination therapy in Part B. Secondary objective: To preliminarily evaluate the anti-tumor activity of AZD4547 combined with tislelizumab in the treatment of locally advanced or metastatic urothelial carcinoma; to evaluate the PK characteristics of AZD4547 combined with tislelizumab after continuous administration. Exploratory objective: To explore the PD characteristics of AZD4547 and the correlation between PD and PK: Part B: Primary objective: To evaluate the anti-tumor activity of AZD4547 combined with tislelizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma with FGFR2/3 alterations. Secondary objectives: To evaluate the other anti-tumor activities of AZD4547 combined with tislelizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma with FGFR2/3 alterations; to evaluate the safety and tolerability of AZD4547 combined with tislelizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma with FGFR2/3 alterations; to evaluate the pharmacokinetic characteristics of AZD4547; Exploratory objectives: To explore the PD characteristics of AZD4547 and the correlation between PD and PK; the relationship between anti-tumor efficacy and the immune and genomic characteristics of the tumor microenvironment; to explore the efficacy of AZD4547 combined with tislelizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma with FGFR2/3 alterations.

Start Date17 Oct 2022

Sponsor / Collaborator

Wuxi Heyu Biomedical Technology Co., Ltd.

NCT05775874 / RecruitingPhase 2

A Sigle-arm，Open Label，Multicenter Study of AZD4547 Combination With Tislelizumab for Patients With Metastatic or Locally Advanced Urothelial Carcinoma (mUC) Harboring Fibroblast Growth Factor Receptor Alterations

This trial is an open, phase II clinical study. The study is divided into two parts: A and B, and the part A evaluate the safety and tolerability of AZD4547 combined with Tislelizumab in patients with locally advanced or metastatic urothelial cancer, determine the recommended dose of midoral AZD4547 combined with Tislelizumab in a Chinese patient population. Part B study will evaluate the efficacy of this recommended dose combined with Tislelizumab in patients with locally advanced or metastatic urothelial cancer with FGFR2 / 3 alterations , and will also further evaluate the safety, tolerability, and PK and PD characteristics of AZD4547 in combination with Tislelizumab.

Start Date30 Sep 2022

Sponsor / Collaborator

Abbisko Therapeutics Co., Ltd.

CTR20210782 / RecruitingPhase 1/2

评价AZD4547在实体瘤患者中的安全性、耐受性及对存在FGFR2/3基因改变的局部晚期或转移性尿路上皮癌患者有效性的Ib/II期临床研究

[Translation] A phase Ib/II clinical study to evaluate the safety, tolerability and efficacy of AZD4547 in patients with solid tumors and locally advanced or metastatic urothelial carcinoma with FGFR2/3 gene alterations

Ib期：主要目的： 1) 评估AZD4547治疗晚期实体瘤的安全性与耐受性，确定最大耐受剂量 2) 确认II期临床研究推荐剂量次要目的： 1) 评估AZD4547单次给药及连续给药的药代动力学特征 2) 评估AZD4547治疗晚期实体瘤的抗肿瘤活性 II期：主要目的： 1) 评估AZD4547治疗存在FGFR2/3基因改变（包括突变和/或融合）的局部晚期或转移性尿路上皮癌患者的客观缓解率次要目的： 1) 评估AZD4547治疗存在FGFR2/3基因改变的局部晚期或转移性尿路上皮癌患者的抗肿瘤活性 2) 评估AZD4547治疗存在FGFR2/3基因改变的局部晚期或转移性尿路上皮癌患者的安全性与耐受性 3) 评估AZD4547治疗存在FGFR2/3基因改变的局部晚期或转移性尿路上皮癌患者的总生存期 4) 评估AZD4547的药代动力学特征

[Translation]

Phase Ib: Main objectives: 1) Evaluate the safety and tolerability of AZD4547 in the treatment of advanced solid tumors and determine the maximum tolerated dose 2) Confirm the recommended dose for Phase II clinical studies Secondary objectives: 1) Evaluate the pharmacokinetic characteristics of single and continuous administration of AZD4547 2) Evaluate the anti-tumor activity of AZD4547 in the treatment of advanced solid tumors Phase II: Main objectives: 1) Evaluate the objective response rate of AZD4547 in the treatment of patients with locally advanced or metastatic urothelial carcinoma with FGFR2/3 gene changes (including mutations and/or fusions) Secondary objectives: 1) Evaluate the anti-tumor activity of AZD4547 in the treatment of patients with locally advanced or metastatic urothelial carcinoma with FGFR2/3 gene changes 2) Evaluate the safety and tolerability of AZD4547 in the treatment of patients with locally advanced or metastatic urothelial carcinoma with FGFR2/3 gene changes 3) To evaluate the overall survival of patients with locally advanced or metastatic urothelial carcinoma and FGFR2/3 gene alterations treated with AZD4547 4) To evaluate the pharmacokinetic characteristics of AZD4547

Start Date16 Jun 2021

Sponsor / Collaborator

Abbisko Therapeutics Co., Ltd.

100 Clinical Results associated with Fexagratinib

100 Translational Medicine associated with Fexagratinib

100 Patents (Medical) associated with Fexagratinib

162

Literatures (Medical) associated with Fexagratinib

01 Jan 2025·BRITISH JOURNAL OF PHARMACOLOGY

Anti‐inflammatory and remyelinating effects of fexagratinib in experimental multiple sclerosis

Article

Author: Böttiger, Gregor ; Bhushan, Sudhanshu ; Berghoff, Martin ; Stadelmann, Christine ; Rajendran, Ranjithkumar ; Karnati, Srikanth ; Shirvanchi, Kian ; Ergün, Süleyman ; Rajendran, Vinothkumar ; Megalofonou, Fevronia‐Foivi ; Gurski, Fynn

Abstract:

Background and Purpose:

FGF, VEGFR‐2 and CSF1R signalling pathways play a key role in the pathogenesis of multiple sclerosis (MS). Selective inhibition of FGFR by infigratinib in MOG35‐55‐induced experimental autoimmune encephalomyelitis (EAE) prevented severe first clinical episodes by 40%; inflammation and neurodegeneration were reduced, and remyelination was enhanced. Multi‐kinase inhibition of FGFR1‐3, CSFR and VEGFR‐2 by fexagratinib (formerly known as AZD4547) may be more efficient in reducing inflammation, neurodegeneration and regeneration in the disease model.

Experimental Approach:

Female C57BL/6J mice were treated with fexagratinib (6.25 or 12.5 mg·kg−1) orally or placebo over 10 days either from time of EAE induction (prevention experiment) or onset of symptoms (suppression experiment). Effects on inflammation, neurodegeneration and remyelination were assessed at the peak of the disease (Day 18/20 post immunization) and the chronic phase of EAE (Day 41/42).

Key Results:

In the prevention experiment, treatment with 6.25 or 12.5 mg·kg−1 fexagratinib prevented severe first clinical episodes by 66.7% or 84.6% respectively. Mice treated with 12.5 mg·kg−1 fexagratinib hardly showed any symptoms in the chronic phase of EAE. In the suppression experiment, fexagratinib resulted in a long‐lasting reduction of severe symptoms by 91 or 100%. Inflammation and demyelination were reduced, and axonal density, numbers of oligodendrocytes and their precursor cells, and remyelinated axons were increased by both experimental approaches.

Conclusion and Implications:

Multi‐kinase inhibition by fexagratinib in a well‐tolerated dose of 1 mg·kg−1 in humans may be a promising approach to reduce inflammation and neurodegeneration, to slow down disease progression and support remyelination in patients.

30 Sep 2024·Aging-US

Retraction of: Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer

Author: Liu, Wei ; Zhan, Yunhong ; Shan, Liping

01 Apr 2024·Hepatology international

Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma

Article

Author: Kawaguchi, Takumi ; Nakamura, Toru ; Koga, Hironori ; Masuda, Atsutaka ; Imamura, Yasuko ; Suzuki, Hiroyuki ; Tanaka, Toshimitsu ; Sakaue, Takahiko ; Hoshida, Yujin ; Iwamoto, Hideki

Abstract:

Background & aims:

Combination immunotherapy refers to the use of immune checkpoint inhibitors (ICI) and molecular-targeted agents (MTA), which have recently been approved for the treatment of advanced hepatocellular carcinoma (HCC). Owing to its relatively low antitumor effect (up to 30%), sequential therapy following ICIs treatment is required in patients with HCC. This study aimed to determine the impact of MTAs on the tumor immune microenvironment (TIME).

Methods:

We established immune syngeneic orthotopic HCC mouse models using Hep-55.1C and Hep-53.4, and treated them with MTAs (lenvatinib, sorafenib, regorafenib, cabozantinib, and DC101 as anti-vascular endothelial growth factor receptor-2 antibodies, and AZD4547 as a fibroblast growth factor receptor (FGFR)-1/2/3/4 inhibitor) for 2 weeks. Subsequently, alterations in the TIME caused by MTAs were evaluated using immunohistochemistry (antibodies for CD3, CD8, Foxp3, Granzyme B, Arginase-1, NK1.1, F4/80, CD11c, PD-1, and PD-L1). We conducted RNA-seq analysis using lenvatinib- and AZD4547-treated tumors. To confirm the clinical relevance of these findings, we analyzed the transcriptome data of human HCC cells (MHCC-97H) treated with various concentrations of lenvatinib for 24 h using RNA-seq data from the Gene Expression Omnibus database.

Results:

The number of Foxp3- and F4/80-positive cells in the TIME was decreased in many MTAs. Cabozantinib increased the numbers in NK1.1-, Granzyme B, and CD11c-positive cells. Lenvatinib and AZD4547 increased the number of CD8, Granzyme B, and PD-L1-positive cells. Gene ontology enrichment analysis revealed that lipid metabolism-related genes were downregulated by lenvatinib and AZD4547. In total, 161 genes downregulated by FGFR inhibition in rodent models overlapped with those downregulated by lenvatinib in human HCC cells.

Conclusions:

In this study, we showed that cabozantinib activated the innate immune system, and lenvatinib and AZD4547, which commonly inhibit FGFR signaling, altered TIME to a hot immune state by downregulating lipid metabolism-related genes. These findings support the therapeutic use of combination immunotherapies.

News (Medical) associated with Fexagratinib

29 Apr 2021

·www.globenewswire.com

Burning Rock and Abbisko Therapeutics Announce Strategic

GUANGZHOU, China, April 29, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Abbisko Therapeutics (“Abbisko”) in companion diagnostics (CDx). The two companies will work together to develop a CDx assay for ABSK091 (formerly known as AZD4547) to advance clinical research and development of the drug. The CDx assay is designed to detect FGFR genetic alterations in patients with urothelial carcinoma. ABSK091 is an innovative small molecule FGFR inhibitor, of which Abbisko has the exclusive global rights for development, manufacture, and commercialization. In prior preclinical and multiple clinical studies, ABSK091 has demonstrated good safety and tolerability profiles, as well as preliminary efficacy in cancer patients harboring FGFR alterations. “In the era of precision medicine, personalized cancer therapy relies on precise diagnosis. Leveraging the leading next generation sequencing (NGS) technology, well-proven lab quality control protocol and integrated service system for pharmaceutical companies, Burning Rock will support its partners in the development of innovative oncology drugs,” said Xinru Mao, Head and Senior Director of Pharmaceutical Business Development, Burning Rock, “ABSK091 has shown the potential to treat patients with FGFR signaling pathway-dependent tumors in previous studies. Our collaboration with Abbisko is expected to maximize each other’s strengths to further advance the standardization of FGFR detection for patients with urothelial carcinoma in China.” “As a potent and selective FGFR inhibitor, ABSK091 has the potential to treat a variety of tumors harboring FGFR alterations. Abbisko has obtained the investigational new drug (IND) approval of ABSK091 from National Medical Products Administration (NMPA) for the treatment of patients with urothelial carcinoma, and will initiate phase Ib/II multi-center clinical trials in China soon,” said Jing Ji, Chief Medical Officer of Abbisko, “We look forward to working with Burning Rock to accelerate the clinical development and advance this innovative drug into market as early as possible to provide a novel treatment option for patients and doctors.” About Burning RockBurning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. For more information about Burning Rock, please visit: ir.brbiotech.com. About Abbisko TherapeuticsFounded in April 2016, Abbisko is an oncology focused biopharmaceutical company dedicated to the discovering and developing innovative medicines for unmet medical needs in China and around the world. The company is founded by a group of seasoned drug hunters with rich research and management experience in both top international pharmaceutical companies and Chinese industrial leaders. It is dedicated to developing immune-oncology and target-based therapies for novel and high potential targets, to develop first-in-class or best-in-class molecular entities. The company has built up an extensive internal discovery pipeline in targeted therapy and immune-oncology, among which, several projects have entered in clinical-stage development. Safe Harbor StatementThis press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

CollaborateInnovative DrugFirst in ClassSmall molecular drug

29 Apr 2021

·www.biospace.com

Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091

GUANGZHOU, China, April 29, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Abbisko Therapeutics (“Abbisko”) in companion diagnostics (CDx). The two companies will work together to develop a CDx assay for ABSK091 (formerly known as AZD4547) to advance clinical research and development of the drug. The CDx assay is designed to detect FGFR genetic alterations in patients with urothelial carcinoma. ABSK091 is an innovative small molecule FGFR inhibitor, of which Abbisko has the exclusive global rights for development, manufacture, and commercialization. In prior preclinical and multiple clinical studies, ABSK091 has demonstrated good safety and tolerability profiles, as well as preliminary efficacy in cancer patients harboring FGFR alterations. “In the era of precision medicine, personalized cancer therapy relies on precise diagnosis. Leveraging the leading next generation sequencing (NGS) technology, well-proven lab quality control protocol and integrated service system for pharmaceutical companies, Burning Rock will support its partners in the development of innovative oncology drugs,” said Xinru Mao, Head and Senior Director of Pharmaceutical Business Development, Burning Rock, “ABSK091 has shown the potential to treat patients with FGFR signaling pathway-dependent tumors in previous studies. Our collaboration with Abbisko is expected to maximize each other’s strengths to further advance the standardization of FGFR detection for patients with urothelial carcinoma in China.” “As a potent and selective FGFR inhibitor, ABSK091 has the potential to treat a variety of tumors harboring FGFR alterations. Abbisko has obtained the investigational new drug (IND) approval of ABSK091 from National Medical Products Administration (NMPA) for the treatment of patients with urothelial carcinoma, and will initiate phase Ib/II multi-center clinical trials in China soon,” said Jing Ji, Chief Medical Officer of Abbisko, “We look forward to working with Burning Rock to accelerate the clinical development and advance this innovative drug into market as early as possible to provide a novel treatment option for patients and doctors.” About Burning Rock Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. For more information about Burning Rock, please visit: ir.brbiotech.com. About Abbisko Therapeutics Founded in April 2016, Abbisko is an oncology focused biopharmaceutical company dedicated to the discovering and developing innovative medicines for unmet medical needs in China and around the world. The company is founded by a group of seasoned drug hunters with rich research and management experience in both top international pharmaceutical companies and Chinese industrial leaders. It is dedicated to developing immune-oncology and target-based therapies for novel and high potential targets, to develop first-in-class or best-in-class molecular entities. The company has built up an extensive internal discovery pipeline in targeted therapy and immune-oncology, among which, several projects have entered in clinical-stage development. Safe Harbor Statement This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. Contact: IR@brbiotech.com

CollaborateInnovative DrugFirst in ClassSmall molecular drug

100 Deals associated with Fexagratinib

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12247

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
FGFR positive Cholangiocarcinoma	Phase 3	US	National Cancer Institute	01 Oct 2014
FGFR positive Cholangiocarcinoma	Phase 3	CA	National Cancer Institute	01 Oct 2014
FGFR3 Mutant Neoplasms	Phase 3	US	National Cancer Institute	01 Oct 2014
FGFR3 Mutant Neoplasms	Phase 3	CA	National Cancer Institute	01 Oct 2014
metastatic non-small cell lung cancer	Phase 3	US	National Cancer Institute	01 Oct 2014
metastatic non-small cell lung cancer	Phase 3	CA	National Cancer Institute	01 Oct 2014
Recurrent Squamous Cell Lung Carcinoma	Phase 3	US	National Cancer Institute	01 Oct 2014
Recurrent Squamous Cell Lung Carcinoma	Phase 3	CA	National Cancer Institute	01 Oct 2014
Metastatic urothelial carcinoma	Phase 2	CN	Wuxi Heyu Biomedical Technology Co., Ltd.	17 Oct 2022
Locally Advanced Urothelial Carcinoma	Phase 2	CN	Abbisko Therapeutics Co., Ltd.	30 Sep 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05086666 (NEWS) Manual	Phase 2	Carcinoma	13	Fexagratinib (伴有FGFR3变异)	gvtfvuzfye(hmblfwtszi) = 未报告与药物相关的4级或以上不良反应 jdgxayuzwh (mwriuvypnx )	Positive	08 Dec 2022
NCT05086666 (NEWS) Manual	Phase 2	Carcinoma	13	Fexagratinib (FGFR3突变)		Positive	08 Dec 2022
NCT01791985 (RADICAL, CTgov)	Phase 1/2	Estrogen receptor positive breast cancer	52	AZD4547	pagdatuqvu(iitqklaauk) = uzqaddukkj ldzrvfxegx (hvbejytihv, aksasjpned - aawsksbwqd) View more	-	22 Aug 2022
NCT01791985 (RADICAL, Pubmed \| Nat Commun) Manual	Phase 1/2	Breast Cancer	52	Anastrozole+Letrozole+AZD4547	kdoymchujp(apgyvsjuto) = jguehnnqfy hpbhkmyzaw (ruijjbbmlt ) View more	-	10 Jun 2022
NCT04439240 (CTgov)	Phase 2	Refractory Malignant Solid Neoplasm \| Advanced Malignant Solid Neoplasm \| Advanced Lymphoma ... View more	52	FGFR Inhibitor AZD4547	qhxeyalnlj(svzzjsghse) = xckpjmdznu mugffvqoej (lxgtfilhhg, vmakfzupla - xkrffbxxkj) View more	-	29 Jun 2021
NCT02965378 (SWOG S1400D \| S1400D, CTgov)	Phase 2/3	FGFR positive Cholangiocarcinoma \| metastatic non-small cell lung cancer \| Recurrent Squamous Cell Lung Carcinoma ... View more	43	Laboratory Biomarker Analysis+FGFR Inhibitor AZD4547	kmllwiwvjn(livmdnhlhq) = yupdvgopwn uyzdrjtair (sodfixjzud, rrjpsbcdwr - gibqrpzhkv) View more	-	27 May 2021
NCT02965378 (SWOG S1400D, Pubmed \| J Thorac Oncol) Manual	Phase 2	squamous cell lung carcinoma Second line FGFR1 Amplification \| FGFR3 Amplification	27	AZD4547	htthzaicxe(uflaftsjay) = ndepcekygu hdfcnhjsrn (vowjybgkpt ) View more	Negative	01 Oct 2019
FRAME Study (WCLC2019)	Not Applicable	Malignant Pleural Mesothelioma Third line	24	AZD4547	dplsjudnqd(pweeokasco) = dgarrfodar rhioriyral (yrgefkvqgw ) View more	Negative	10 Sep 2019
NCT00979134 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Lung Cancer	15	AZD4547	cibdkkwzdj(egckekmnlz) = aotdkzpoll rqirqyxyov (zjyilkklsy ) View more	Positive	15 Sep 2017
NCT01213160 (Pubmed \| Invest New Drugs) Manual	Phase 1	Solid tumor FGFR mutations \| FGFR aberrations	34	AZD4547 (dose-escalation part)	byenmtvqbh(pcewcyceah) = Common grade ≥3 AEs were nausea (12% of patients) and neutropenia (9%). bgeoukrfbz (jgseienwfr ) View more	Positive	01 Aug 2017
NCT01213160 (Pubmed \| Invest New Drugs) Manual	Phase 1	Solid tumor FGFR mutations \| FGFR aberrations	34	AZD4547 (dose-expansion part)		Positive	01 Aug 2017
NCT01791985 (RADICAL, ASCO2017) Manual	Phase 1/2	Estrogen receptor positive breast cancer	-	Anastrozole+Letrozole+AZD4547	zuawmftsjr(dlvsacyosz) = wkdlwafjrj upozynrtua (nlcrixorzf, -4 to 17) View more	Positive	04 Jun 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis